Previous studies suggested the expression of mRNA, coding for CNP, exclusively in the central nervous system. In the present study, using the polymerase chain reaction (PCR) technique instead of the less sensitive Northern blot hybridization, CNP-specific sequences have also been detected in rat atria and ventricles of the heart as well as in organs of the immune system (thymus, spleen and lymph nodes). Parallel PCR-assays documented ANP-mRNA in these tissues. To verify specificity of the PCR-products, Southern blots have been hybridized with a third internal oligonucleotide and amplicification products have been sequenced. The relative level of CNP-mRNA in these tissues was estimated to be in the range of l-9% of total brain CNP transcripts. The results suggest that the peptide may have a peripheral as well as a central site of action. In light of its pronounced effect on cell proliferation, particular interest should focus on a possible role of CNP in the immune system.
INTRODUCTION
C-type natriuretic peptide (CNP), a new member of the natriuretic peptide family (1) shows features distinct from ANP and BNP, as CNP-mRNA expression has been restricted to the central nervous system (2) . Furthermore, CNP selectively binds to the B-subtype of natriuretic peptide receptors which was reported to be mainly expressed in the brain (3) . Accordingly, a central site of action for this peptide has been suggested (2, 3) . Recently, however, by means of the PCR-technique the Btvoe receotor transcript has been detected in the periphery #,5), proposing the presence of the corresponding ligand, CNP, as well as a functional role of this peptide in peripheral organs. Indeed, a most recent report communicates the presence of CNP in cultured endothelial cells (6) . The aim of the present study was to investigate the expression of mRNA coding for CNP in peripheral tissues by use of the highly sensitive PCR-technique. Emphasis was put on cardiac tissues, which are known to be the main site of synthesis for ANP and BNP, and on organs of the immune system, knowing that ANP, a member of the natriuretic peptides, is expressed in certain immunocompetent cells (7, 8) .
MATERIALS AND METHODS
mRNA extraction: Total RNA from rat tissues (Sprague Dawley, male, lOO-1209, n=3) was extracted using the guanidinium thiocyanate-CsC12 technique. The integrity of the RNA preparation was assessed by gel electrophoresis. and mRNA was isolated subsequently by use of a kit (PolyATtract, Promega, FRG). mRNA was estimated by UV adsorbance and additionally quantified by dot blot hybridization to end-labelled p(dT)12-18 according to (9) . cDNA svnthesis: 1 mg mRNA was employed for reverse transcriptase reaction, using p(dT)12-l and avian myeloblastosis virus reverse transcriptase B-J romega, RTsystem kit).
PCR amolification of ANP-and CNP transcripts: PCR for ANP was conducted as previosly described (9) . Briefly, various amounts of cDNA were added to 700 ng each of sense primer (5'-CAGCATGGGCTCCTTCTCCA-3') and antisense orimer (5'-GTCAATCCTACCCCCGAAGCAGCT-3') corresponding'to the first and second exon of the rat ANP gene (IO). 25-40 cycles of PCR amplification, using 2.5 units of Taq DNA polymerase (Boehringer, Mannheim, FRG), were performed. Amplification products (430 bp) were separated by gel electrophoresis (2.5% agarose), stained by ethidium bromide, visualized under UV and blotted to nylon membranes (Hybw-N, Amersham, FRG). An end-labelled oligonucleotide k P-ATP 5000 i/mmol, T4-polynucleotide kinase) corresponding t f coding sequences located between the two PCR primers f5'-CTGCTAGACCACCTGGAGGAG-3') was used for hybridization. Amplification and identification of CNP sequences were conducted as decribed for ANP. exceot for the use of the primers VOOng, each):
'ae,ndSean antisense orimer /5'-CGCTGCACTAACATCCCAGACCGC-3') corresponding &J sequences in the first and second exon of the rat CNP gene (2) were used. The 553 bp comprising CNP amplification products were analysed as described above. For hybridization, a noncoding primer located in the second exon (5'-ATGGAGCCGATCCGGTCCAGCTT-3') was employed. Three different mRNA samoles of each tissue were employed and PCR amplification of each sample was conducted at least twice. For both amplification procedures and each tissue sample various initial amounts of cDNA templates and numbers of PCR cycles were tested to ensure exponential amplification of the fragments of interest.
Semiauantification of PCR-Droducts: Estimation of CNP-as well as ANP-mRNA tissue levels was conducted by densitometry of the corresponding hybridization bands (11) . The values for either brain (CNP)-or atria (ANP) amplification products were assigned to an arbitrary unit of 100. Densitometry values are presented as percentage.
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Sequencing of CNP-transcripts: PCR products from the various tissues were sequenced directly on an automated system using Taq DNA polymerase and fluorescence labelled dideoxynucleotides. Sequencing was done at least once in each direction as described (12) .
RESULTS
Amolification of CNP-sequences in the heart and immune OraanS cDNA samples corresponding to 0.550 ng total mRNA from ventricular and atrial tissues were subjected to 30 PCR cycles. Rat genomic DNA as well as cDNA from rat brain were employed as positive controls for the expected 824 bp and 554 bp comprising amplification products. cDNA (50 ng mRNA) from liver, which has been reported to express neither ANP nor BNP (9) and omission of cDNA, respectively, were employed to control for nonspecific amplification. To further support the CNP-specificity of the PCR-products, SoutheB blots were carried out by hybridization with a -P-end-labelled oligonucleotide, which corresponds to a cDNA sequence located between the two PCR-primers. As shown in 
Seauencina of CNP-amplification products
To verify the CNP-specificity of the amplification products, an aliquot thereof was sequenced using the same set of primers (12) . The sequence was virtually identical to the corresponding DNA sequence of the rat CNP-gene (2) (data not shown).
Relative auantification of PCR amplification oroducts The densitometric evaluation of the CNP amplification products is presented as percentage of the brain value (Fig. 2) . The signal for CNP mRNA is clearly strongest in the brain, confirming the predominant central expressron of the peptrde (1,2) . However, atria and ventricle also contain CNP-specific PCR-products in the range of 5-9 % of the brain. CNP-products of the thymus, spleen and lymph nodes amount to approximately l-5% of that of the brain (Fig. 2) . In contrast, it is well known that ANP is mainly synthesized in the heart atria and to a substantial amount in the ventricles (i.e. approximately 6% of the atrial PCR transcripts). The amount of PCR-generated ANPsequences in the brain and the lymphoid organs were estimated to range between 0.02% and 1% of the atrial products (data not shown). DISCUSSION CNP-specific mRNA in mammals has been detected in the central nervous system. Thus, CNP was originally thought to represent the brain form of the natriuretic peptide family (l-3). However, we report here CNP-specific amplification products in peripheral tissues, such as the heart atria and ventricles as well as in organs of the immune s 8 stem, using the highly sensitive PCR technique. The P R products have been sequenced in order to verify the corresponding sequence of the CNP-gene (2, 12) . Semiquantitative comparison of CNP-expression in these tissues reveal that atrial and ventricular mRNA coding for CNP ranges between 5-9% of that in the brain. PCR products in thymus, spleen and lymph nodes amount to approximately l-5% of those obtained from the brain. Thus, our data confirm the predominant central expression of CNP, but provide strong evidence that CNP-mRNA is not restricted to the CNS, as originally proposed (i-3). The oresence of CNP-mRNA in peripheral tissues has actually been postulated before (4,5j, but failed to be detected bv conventional mRNA analvsis (2.16). This proposal was based on various experimental findings, such as the GNP-specific B-receptor. This receptor, initially believed to be confined to the central nervous system (3), has also been found in the periphery by means of PCR analysis as well as by autoradiographic visualisation (45, 17). Secondly, small amounts of immunoreactive CNP-like peptide were found by radioimmunoassay in the kidney and-intestine (181. and most recentlv also in cultured epithelial cells ' (6) : No material was deported for other peripheral tissues including the heart ventricles (18) . Based on the predominant central site of synthesis of CNP, as compared to ANP/BNP, the peptide was suggested to act as a neurotransmitter or neuromodulator rather than a cardiac hormone (I-5, 19). Pharmacological actions distinct from those of ANP and BNP have been proposed for CNP. as it has been shown to stimulate water intake in r&contrasting the action of ANP (19). Our data, however, suggest that the action of CNP is not confined to the central nervous system With respect to the presence of CNP production in the immune system, particular interest should be focused on its pronounced antimitogenic and antiproliferative effect, initially observed in cultered smooth muscle cells (20) . CNP may function in the regulation of cell proliferation within the immune system. The peptide may constitute a further substance shared by the neuroendocrine-and the immune system supporting the notion of a functional interaction between both systems (21) .
